Access


Nature Medicine 7, 369 - 372 (2001)
doi:10.1038/85525

Imaging of amyloid-bold beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy

Brian J. Bacskai1, Stephen T. Kajdasz1, Richard H. Christie1, Cordelia Carter1, Dora Games2, Peter Seubert2, Dale Schenk2 & Bradley T. Hyman1

  1. Alzheimer's Disease Research Laboratory, Massachusetts General Hospital, Charlestown, Massachusetts, USA
  2. Elan Pharmaceuticals, South San Francisco, California, USA

Correspondence to: Bradley T. Hyman1 e-mail: b_hyman@helix.mgh.harvard.edu

Alzheimer disease (AD) can be diagnosed with certainty only post-mortem, by histologically demonstrating insoluble aggregates of amyloid-bold beta peptide, called senile plaques1, 2, 3, 4. Direct imaging of these lesions in the living brain would revolutionize early diagnosis of AD.

$rb.Type.Code